AR083502A1 - Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina - Google Patents

Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina

Info

Publication number
AR083502A1
AR083502A1 ARP110103892A ARP110103892A AR083502A1 AR 083502 A1 AR083502 A1 AR 083502A1 AR P110103892 A ARP110103892 A AR P110103892A AR P110103892 A ARP110103892 A AR P110103892A AR 083502 A1 AR083502 A1 AR 083502A1
Authority
AR
Argentina
Prior art keywords
triazol
fluoro
methyl
salt
tosilada
Prior art date
Application number
ARP110103892A
Other languages
English (en)
Spanish (es)
Inventor
Yongbo Liu
Bing Wang
Daniel Chu
Shichun Peng
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083502(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR083502A1 publication Critical patent/AR083502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP110103892A 2010-10-21 2011-10-20 Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina AR083502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40547610P 2010-10-21 2010-10-21

Publications (1)

Publication Number Publication Date
AR083502A1 true AR083502A1 (es) 2013-02-27

Family

ID=44903424

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103892A AR083502A1 (es) 2010-10-21 2011-10-20 Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina

Country Status (24)

Country Link
US (3) US8735392B2 (enExample)
EP (2) EP2630146B1 (enExample)
JP (6) JP2013540158A (enExample)
KR (4) KR20190120458A (enExample)
CN (1) CN103282365B (enExample)
AR (1) AR083502A1 (enExample)
AU (2) AU2011317040B2 (enExample)
BR (1) BR112013009117A2 (enExample)
CA (1) CA2814581C (enExample)
CY (1) CY1123356T1 (enExample)
DK (1) DK2630146T3 (enExample)
ES (1) ES2816600T3 (enExample)
HU (1) HUE051535T2 (enExample)
IL (2) IL225789B (enExample)
MX (1) MX362563B (enExample)
NZ (1) NZ609490A (enExample)
PL (1) PL2630146T3 (enExample)
PT (1) PT2630146T (enExample)
RU (1) RU2598606C3 (enExample)
SG (2) SG10201710578TA (enExample)
SI (1) SI2630146T1 (enExample)
TW (2) TWI557123B (enExample)
WO (1) WO2012054698A1 (enExample)
ZA (1) ZA201302810B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2326650B9 (en) 2008-08-06 2014-09-10 BioMarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CA2944788C (en) 2009-06-29 2023-08-22 Agios Pharmaceuticals, Inc. Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AU2011212928B2 (en) 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
MX340319B (es) * 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
ES2816600T3 (es) 2010-10-21 2021-04-05 Medivation Tech Llc Sal tosilato de (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-8,9-dihidro-2H-pirido[4,3,2-de]ftalazin-3(7H)-ona cristalina
KR101873543B1 (ko) 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103857661B (zh) * 2011-08-11 2016-11-16 拜耳知识产权有限责任公司 1,2,4‑三唑基取代的酮烯醇
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
HK1213798A1 (zh) 2012-10-15 2016-07-15 安吉奥斯医药品有限公司 治療性化合物和組合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
DK3105226T3 (da) 2014-02-13 2019-10-14 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
RS62178B1 (sr) * 2014-03-14 2021-08-31 Les Laboratoires Servier Sas Farmaceutske kompozicije terapeutski aktivnih jedinjenja
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EA201790290A1 (ru) * 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
DK3307271T3 (da) 2015-06-11 2023-10-09 Agios Pharmaceuticals Inc Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
MA71411A (fr) 2015-10-15 2025-04-30 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
CA3003422A1 (en) * 2015-10-26 2017-05-04 Medivation Technologies Llc Treatment of small cell lung cancer with a parp inhibitor
US10246461B2 (en) 2016-02-29 2019-04-02 Genentech, Inc. Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CA3078806A1 (en) 2017-10-13 2019-04-18 Merck Patent Gmbh Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
WO2019235822A1 (ko) 2018-06-04 2019-12-12 엘지전자 주식회사 어파인 움직임 예측을 이용하여 비디오 신호를 처리하는 방법 및 장치
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US10942500B2 (en) * 2018-06-11 2021-03-09 Purdue Research Foundation System architecture and method of processing data therein
US10284866B1 (en) * 2018-07-02 2019-05-07 Tencent America LLC Method and apparatus for video coding
CN112424671B (zh) 2018-07-13 2023-10-27 奇跃公司 用于显示双目变形补偿的系统和方法
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
JP7713934B2 (ja) * 2019-10-10 2025-07-28 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
KR20230107647A (ko) 2020-11-13 2023-07-17 화이자 인코포레이티드 탈라조파립 연질 젤라틴 캡슐 투여 형태
CA3203814A1 (en) 2020-12-07 2022-06-16 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
BR112023018906A2 (pt) 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
IL163562A0 (en) * 2002-02-19 2005-12-18 Ono Pharmaceutical Co fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2505876A1 (en) 2002-11-12 2004-05-27 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
MXPA05009661A (es) * 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
JP4824566B2 (ja) 2003-05-28 2011-11-30 エーザイ インコーポレーテッド Ｐａｒｐを阻害するための化合物、方法、および医薬組成物
JP5084269B2 (ja) 2004-02-18 2012-11-28 アストラゼネカ アクチボラグ テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
WO2009024190A1 (en) 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
JP2011511078A (ja) 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
EP2326650B9 (en) 2008-08-06 2014-09-10 BioMarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MX2011001563A (es) 2008-08-12 2011-03-04 Boehringer Ingelheim Int Procedimiento para la preparacion de compuestos de piperazina sustituidos con cloalquilo.
AU2011212928B2 (en) 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
ES2816600T3 (es) 2010-10-21 2021-04-05 Medivation Tech Llc Sal tosilato de (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-8,9-dihidro-2H-pirido[4,3,2-de]ftalazin-3(7H)-ona cristalina
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
US20160280691A1 (en) 2013-11-07 2016-09-29 Biomarin Pharmaceutical Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

Also Published As

Publication number Publication date
HUE051535T2 (hu) 2021-03-01
IL225789A0 (en) 2013-06-27
CA2814581A1 (en) 2012-04-26
SI2630146T1 (sl) 2020-12-31
CN103282365B (zh) 2017-12-29
JP2017061526A (ja) 2017-03-30
AU2017201564B2 (en) 2019-05-09
EP2630146A1 (en) 2013-08-28
EP2630146B1 (en) 2020-07-01
TWI643858B (zh) 2018-12-11
AU2011317040A1 (en) 2013-05-09
IL225789B (en) 2019-12-31
PL2630146T3 (pl) 2020-11-02
CA2814581C (en) 2019-02-12
US8735392B2 (en) 2014-05-27
KR20140009181A (ko) 2014-01-22
JP2024150772A (ja) 2024-10-23
ZA201302810B (en) 2014-06-25
US20120129865A1 (en) 2012-05-24
TW201713656A (en) 2017-04-16
NZ609490A (en) 2015-06-26
US20140228369A1 (en) 2014-08-14
BR112013009117A2 (pt) 2016-07-19
MX362563B (es) 2019-01-25
TW201307345A (zh) 2013-02-16
WO2012054698A1 (en) 2012-04-26
ES2816600T3 (es) 2021-04-05
SG189939A1 (en) 2013-06-28
SG10201710578TA (en) 2018-02-27
JP2013540158A (ja) 2013-10-31
AU2011317040B2 (en) 2016-12-08
US10189837B2 (en) 2019-01-29
RU2013123036A (ru) 2014-11-27
EP3757106A1 (en) 2020-12-30
RU2598606C2 (ru) 2016-09-27
CY1123356T1 (el) 2021-12-31
PT2630146T (pt) 2020-07-20
KR20180069132A (ko) 2018-06-22
JP2019034951A (ja) 2019-03-07
TWI557123B (zh) 2016-11-11
KR20210028747A (ko) 2021-03-12
DK2630146T3 (da) 2020-08-10
IL271497A (en) 2020-02-27
AU2017201564A1 (en) 2017-03-23
US20180009806A1 (en) 2018-01-11
JP2020169209A (ja) 2020-10-15
JP2022140637A (ja) 2022-09-26
MX2013004195A (es) 2013-07-22
RU2598606C3 (ru) 2021-12-20
CN103282365A (zh) 2013-09-04
KR20190120458A (ko) 2019-10-23

Similar Documents

Publication Publication Date Title
AR083502A1 (es) Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
MX377635B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CO6640297A2 (es) Pirazolo[1,5-a] pirimidinas como agentes antivirales
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CR20180307A (es) Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6781507A2 (es) Novedosos derivados heterociclicos
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
GT201500069A (es) Piridinonas bicìclicas novedosas
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2013000866A1 (es) Sales cristalinas oxalato y fosfato del conjugado naloxolpolietilenglicol; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento del dolor.
BR112012009388A2 (pt) derivados de apogossipolone como agentes anticâncer
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
NI201300100A (es) Derivados de tieno [2, 3-d] pirimidina y su uso para tratar arritmias
MX2013015001A (es) Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
UY33099A (es) Derivados de 9h-piridino[3,4-b]indol disustituidos, metodo para prepararlos, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en la terapia del cancer.
CL2013002100A1 (es) Compuestos derivados de aminostatina, para aplicacion intraarticular; procedimiento para prepararlos; medicamento; kit farmaceutico; preparacion farmaceutica; procedimiento de obtencion de la preparacion farmaceutica; y uso de esta preparación para tratar o prevenir artrosis y lesiones traumaticas de los cartilagos, entre otras.

Legal Events

Date Code Title Description
FC Refusal